CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-95775

First Posted Date: 2019-09-13

Last Posted Date: 2022-02-01

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT04089527

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷
Hopital Saint Louis, Paris, France

and more 2 locations

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3

Recruiting

Conditions: Myelodysplastic Syndromes (MDS)
Beta-thalassemia
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Interventions: Drug: Luspatercept

First Posted Date: 2019-08-21

Last Posted Date: 2025-05-29

Lead Sponsor: Celgene

Target Recruit Count: 665

Registration Number: NCT04064060

Locations: 🇧🇪
Local Institution - 184, Leuven, Belgium
🇧🇬
Local Institution - 220, Boulevard, Sofia, Bulgaria
🇧🇬
University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria

and more 140 locations

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Phase 2

Terminated

Conditions: Liver Cirrhosis
Non-alcoholic Fatty Liver Disease

Interventions: Drug: CC-90001
Drug: Placebo

First Posted Date: 2019-08-07

Last Posted Date: 2023-06-07

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT04048876

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Digestive Disease Associates, PA, Catonsville, Maryland, United States

and more 139 locations

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Phase 1

Terminated

Conditions: Astrocytoma
Glioblastoma

Interventions: Drug: CC-90010

First Posted Date: 2019-08-06

Last Posted Date: 2024-07-05

Lead Sponsor: Celgene

Target Recruit Count: 20

Registration Number: NCT04047303

Locations: 🇺🇸
Local Institution - 101, Tampa, Florida, United States
🇺🇸
Local Institution - 102, Boston, Massachusetts, United States
🇪🇸
Local Institution - 302, Madrid, Spain

and more 1 locations

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Completed

Conditions: Myelodysplastic Syndromes
Lymphoma, Mantle-Cell
Lymphoma, Follicular

Interventions: Drug: REVLIMID®

First Posted Date: 2019-07-29

Last Posted Date: 2025-03-11

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04036448

Locations: 🇰🇷
Local Institution - S10, Jeonju-si, Korea, Republic of
🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Local Institution - S06, Seoul, Korea, Republic of

and more 23 locations

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-99712
Drug: BMS-986405

First Posted Date: 2019-07-29

Last Posted Date: 2024-01-30

Lead Sponsor: Celgene

Target Recruit Count: 160

Registration Number: NCT04036461

Locations: 🇺🇸
Local Institution - 102, Seattle, Washington, United States
🇺🇸
Local Institution - 104, Dallas, Texas, United States
🇨🇦
Local Institution - 202, Toronto, Ontario, Canada

and more 17 locations

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-92480
Drug: Dexamethasone
Drug: Bortezomib
Drug: Isatuximab
Drug: Carfilzomib
Drug: Elotuzumab
Drug: Daratumumab

First Posted Date: 2019-06-18

Last Posted Date: 2024-11-28

Lead Sponsor: Celgene

Target Recruit Count: 424

Registration Number: NCT03989414

Locations: 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿
Local Institution - 802, Brno, Czechia
🇨🇿
Local Institution - 801, Ostrava-Poruba, Czechia

and more 46 locations

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Phase 1

Completed

Conditions: Healthy Volunteers
Hepatic Impairment

Interventions: Drug: Fedratinib

First Posted Date: 2019-06-12

Last Posted Date: 2023-03-17

Lead Sponsor: Celgene

Target Recruit Count: 39

Registration Number: NCT03983161

Locations: 🇺🇸
University Of Miami Miller School Of Medicine, Miami, Florida, United States
🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fedratinib
Drug: Rifampin
Drug: Efavirenz

First Posted Date: 2019-06-12

Last Posted Date: 2020-08-21

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT03983239

Locations: 🇺🇸
Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Phase 1

Terminated

Conditions: Psoriasis
Healthy Volunteers

Interventions: Drug: CC-92252
Other: Placebo

First Posted Date: 2019-06-03

Last Posted Date: 2021-08-30

Lead Sponsor: Celgene

Target Recruit Count: 131

Registration Number: NCT03971825

Locations: 🇩🇪
Charite Research Organisation GmbH, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy